ABSTRACT
third consensus conference on methodology of clinical trials of antipsychotics had concluded that the optimal duration of short term trials is between 4-8 weeks, it can only indicate a very preliminary & tentative outcome unless it is in individuals who had been previously drug free.
According to Kane (1994) , the data from multicentre trials suggest a bimodal response pattern, wherein the 6 mg and 16 mg dose of Risperidone are most effective. Buckley (1997) reported that the modal dose of Risperidone in clinical practice in the united states is 4.6 mg daily. Danik & Goverdhan (1963) ; Mountain (1963) have reported success with use of high dosages of haloperidol in the acutely Psychotic patients, while Fitzgerald (1969) & Anderson et al. (1976) had all reported high improvement rates with low dosages of Haloperidol in the acutely ill Psychotic patients.
Khannaetal. (1997) in an Indian trial with low & high dosages of haloperidol on a sample of Acute & transient Psychotic disorders (ICD-10) did not report any significant difference in the improvement rate between the two groups.
According to Kammen and Marder (1995) , 0.6 mg of Risperidone is equivalent to 100 mg of Chlorpromazine & 2 mg of haloperidol is equivalent to 100 mg of Chlorpromazine.
The aim of the present study is to compare 4 mg of Risperidone (RIS) with near equivalent doses of Haloperidol (HAL) for outcome of clinical symptomatology at short term in first episode drug naive acute & transient Psychotic disorder (F23, ICD-10).
MATERIAL AND METHOD
The study group consisted of indoor patients in the department of Psychiatry at Gauhati Medical College and Hospital, Guwahati.
Subjects were diagoned as per International Classification of Disease -10 criteria for acute and transient psychotic disorder (F23). The diagnosis of the cases were reviewed by the senior consultant after the initial workup of the patients by the Post-Graduate residents in the department of Psychiatry.
The sample for the study consisted of subjects who fulfilled the following : Selection criteria : (1) Age between 16 and 55 years, (2) Patients in the first episode of the disorder, (3) Patients who were free from antipsychotic drug treatment prior to the period of initial assessment, (4) No past history of any Psychiatric morbidity.
The exclusion criteria are the following : (1) Severe medical illness i.e., presence of any physical disorders requiring active medication, or pregnancy & lactation, (2) Patients having neuropsychiatric illness such as epilepsy, mental retardation, drug-induced psychosis, substance abuse disorder, etc. (3) Other psychiatric illness such as bipolar disorder, schizophrenia, etc.
The patients fulfilling the selection criteria were randomly assigned to either risperidone 4 mg (equivalent to 666.67 mg of chlorpromazine) or haloperidol 15 mg (equivalent to 750 mg of chlorpromazine) in a single blind four week protocol. They were administered the semistructured proforma of Brief Psychiatric rating Scale (Overall et al.,1962) at Day 0, Day 7, Day 14 and Day 28. The dimension of psychopathology was interpreted by scoring subjects on the four BPRS factors (Overall & Gorham,1962) viz.
(1) THINKING DISTURBANCE (consist of conceptual disorganization, hallucinatory behaviour, unusual throught content).
(2) HOSTILE SUSPICIOUSNESS (consist of items hostility, suspiciousness and unco-operativeness). (3) WITHDRAWAL RETARDATION (consist of emotional withdrawal, motor retardation, blunted affect). (4) ANXIOUS DEPRESSION (consist of anxiety, guilt, depression).
A high inter-rater reliability was achieved in the administration of the BPRS (correlation co-efficient r=1) prior to the onset of the protocol.
Similarly the Global Assessment of Functioning Scale (GAF) was administered at Day 0, Day 7, Day 14 and Day 28.
The subjects were also assigned oral trihexiphenidyl 6 mg for extrapyramidal symptoms (EPS), and lorazepam 2 mg. at bedtime, if required for sedation, which were duly recorded in each case. Statistical analysis : Carried out by using the Paired *t' test and Fisher's t test.
RESULTS
Thirty-five patients gave full informed consent and were included in the study (HAL group=18 & RIS group=17) . Five patients dropped out of the study prior to completion of 7 days of protocol. Thus thirty patients completed the 4-week study protocol (HAL=15 & RIS = 15). Table 1 sh<?ws the Distribution of sociodemographic variables in the Haloperidol & Risperidone groups Results indicate no major difference in the distribution of diagnostic categories between the two groups a,id the majority had acute schizophrenia like psychotic disorders (Table 2) . Results on comparision of clinical variable between the two groups indicate no difference in the duration of illness prior to initial assessment ; no major difference in distribution of precipitating factors in the three months preceding the onset of illness; and no with those in the HAL group (Table 3) .
Result (Table 4 ) on analysis of BPRS for changes in score between respective days of assessment in HAL group & RIS group, show that the rate of improvement is highly significant (p<0.001) between day 0-7; day 0-14; & day 0-28. In the HAL group the rate of improvement is more significant in the first two weeks (p<0.001) than the last two weeks (p<0.05). In the RIS group, the rate of improvement in the frst two weeks and the last two weeks are equally significant (p<0.001). On analysis, results on GAF scale (Table 4) indicate that in both the groups, the rate of improvement of global fuctioning between day 0 & 7, day 0 & 14, day 0 Table 5a , shows comparison of BPRS score between the two groups at respective days of assessment and indicate no significant difference in lowering of BPRS scores at day 0, 7,14 & 28 (p<0.05) . Similarly comparison of GAF score (Table 5 ) indicate no significant difference in the increase of scores between both the groups at day 0, 7, 14 & 28 (p>0.05) .
TABLE 4 COMPARISON OF CHANGES IN (a) B.P.R.S. (b) G.A.F. SCORES BETWEEN RESPECTIVE DAYS OF ASSESSMENT IN HALOPERIDOL & RISPERIDONE GROUPS
Comparison of scores (Table 6 ) between HAL group & RIS group at respective days of assessment indicate that at day 14, the score on THINKING DISTURBANCE in RIS group is significantly lower than that of HAL group (p<0 05); At day 14, the score on HOSTILE SUSPICIOUSNESS in RIS group is significantly lower than that of HAL group (p<0.05); At day 7, WITHDRAWAL RETARDATION in the RIS group is significantly lower than that of HAL group (p<0.05); whereas at day 0,7,14 & 28, the analysis of ANXIOUS-DEPRESSION show no significant difference between the two groups (p>0.05).
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DISCUSSION
Our findings suggest that Risperidone is of comparable efficacy to Haloperidol in the overall improvement of clinical symptomatology in Acute Psychosis, which is corroborated by Grant & Filton (1994) , Min et al. (1993) and Umbricht& Kane (1995) .
The findings of significant improvement of 'Thinking Disturbance' and 'Hallucinatory Behaviour' by Day 14 in the Risperidone group, suggests the superiority of Risperidone over Haloperidol in positive symptoms in Acute Psychosis during the early phase of treatment. This efficacy has also been advocated by Cardonix et al. (1995) and McEvoy (1994) .
Our findings of early response to 'Hostility' and 'Suspiciousness' in the subscale of "Hostile Suspiciousness in the RIS group, has been reported earlier by Czober et al.(1995) , who suggested Risperidone's greater selective efficacy on Hoslitity when compared to Holoperidol and Placebo and said this suggests encouragement in the use of Risperidone as a treatment for patients showing frequent physical aggression. A different pharmacological mechanism of action of Risperidone, rather than only 5HT 2 . A & weak D 2 blockage may be responsible for this outcome (Meltzer 1995) .
Worsening of, 'Withdrawal Retardation' in general and 'Emotional Withdrawal' a component of 'Withdrawal Retardation' in particular by Day 7 in the HAL group, contrary to the effectivity of Risperidone for the same symptomatology has also been reported by Cardonix (1995) , Marder & Meilbach (1994) and Daradkeh et al. (1996) . All these authors suggested the effectivity of Risperidone in negative symptoms.
The use of trihexyphenidyl for Extrapyramidal symptoms in 40% of subjects in RIS group by Day 28, is similar to the findings of Emsley et al.(1995) who concluded that the risk of EPS in the first episode Schizophernic patients treated with Risperidone is considerably higher (close to 60%) than earlier studies, but is still significantly less than in a control group treated with Haloperidol. We used trihexyphexnidyl in 100% of subjects in the HAL group by Day 28. Owens (1994) and Min et al. (1993) too concluded that the severity of EPS in the RIS group is significantly less than in the HAL group. We can suggest that early worsening of 'Motor Retardation' a component in the subscale of 'Withdrawal Retardation' in HAL group as well as in the RIS group is because of the development of EPS, and subsequent recovery at the end of the protocol can also be attributed to the use of trihexyphenidyl.
The rate of improvement of 'Guilt' suggest the efficacy of Risperidone in depressive symptoms. According to Abel et al. (1977) depressive symptoms in Schizophrenia maybe related to the overactivity of 5HT 2 A/ 2 C receptors and drugs which block this receptor might be useful in the treatment of these symptoms.
The highly significant rate of improvement of'Anxiety' in the 'Anxious Depression' subscale in the HAL group, can be attributed to the anxiolytic effect of Haloperidol. However to be fair, Kaplan and Sadock (1994) suggest use of
